Sylvest Advisors LLC Takes $744,000 Position in Amgen Inc. (NASDAQ:AMGN)

Sylvest Advisors LLC purchased a new position in Amgen Inc. (NASDAQ:AMGN - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 2,853 shares of the medical research company's stock, valued at approximately $744,000.

Several other large investors have also recently made changes to their positions in AMGN. Capital Performance Advisors LLP acquired a new position in Amgen during the 3rd quarter valued at about $25,000. Legacy Investment Solutions LLC acquired a new position in Amgen during the 3rd quarter valued at about $29,000. Matrix Trust Co acquired a new position in Amgen during the 3rd quarter valued at about $36,000. Heck Capital Advisors LLC purchased a new stake in Amgen during the 4th quarter valued at about $36,000. Finally, Livelsberger Financial Advisory purchased a new stake in Amgen during the 3rd quarter valued at about $56,000. 76.50% of the stock is owned by institutional investors.

Amgen Trading Up 0.5 %

Amgen stock traded up $1.40 during trading on Friday, reaching $285.42. 3,799,348 shares of the company were exchanged, compared to its average volume of 2,746,697. Amgen Inc. has a 52-week low of $253.30 and a 52-week high of $346.85. The company has a market capitalization of $153.42 billion, a P/E ratio of 36.55, a PEG ratio of 2.85 and a beta of 0.56. The company has a debt-to-equity ratio of 7.55, a current ratio of 1.32 and a quick ratio of 0.96. The stock's 50 day simple moving average is $271.06 and its two-hundred day simple moving average is $304.33.

Amgen (NASDAQ:AMGN - Get Free Report) last announced its quarterly earnings data on Wednesday, October 30th. The medical research company reported $5.58 EPS for the quarter, topping analysts' consensus estimates of $5.11 by $0.47. Amgen had a return on equity of 168.35% and a net margin of 13.00%. The firm had revenue of $8.50 billion for the quarter, compared to the consensus estimate of $8.50 billion. During the same quarter last year, the business posted $4.96 earnings per share. The firm's revenue was up 23.2% compared to the same quarter last year. On average, equities research analysts expect that Amgen Inc. will post 19.56 earnings per share for the current fiscal year.

Amgen Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, February 14th will be given a $2.38 dividend. The ex-dividend date is Friday, February 14th. This represents a $9.52 dividend on an annualized basis and a yield of 3.34%. This is an increase from Amgen's previous quarterly dividend of $2.25. Amgen's payout ratio is currently 121.90%.

Wall Street Analysts Forecast Growth

AMGN has been the topic of several research analyst reports. Wolfe Research initiated coverage on Amgen in a research note on Friday, November 15th. They set a "peer perform" rating on the stock. Piper Sandler dropped their price target on Amgen from $344.00 to $310.00 and set an "overweight" rating on the stock in a research note on Thursday, January 2nd. Truist Financial dropped their price target on Amgen from $333.00 to $298.00 and set a "hold" rating on the stock in a research note on Wednesday, January 8th. Deutsche Bank Aktiengesellschaft dropped their price target on Amgen from $305.00 to $285.00 in a research note on Wednesday, November 27th. Finally, Royal Bank of Canada restated an "outperform" rating and issued a $324.00 target price on shares of Amgen in a research note on Friday, January 24th. Two investment analysts have rated the stock with a sell rating, twelve have assigned a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, Amgen has an average rating of "Hold" and an average target price of $314.00.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.